诺华制药(NVS.US)大股东呼吁改组董事会,以改善公司治理。此前该公司股价因连续试验受挫于本周创下纪录跌幅。大股东Da

智通财经
Sep 10
诺华制药(NVS.US)大股东呼吁改组董事会,以改善公司治理。此前该公司股价因连续试验受挫于本周创下纪录跌幅。大股东David Samra表示:“历任董事长在收购方面令人失望,公司需要改变对交易的监督方式。”他还敦促诺华董事长Giovanni Caforio采取行动。Samra说:“我认为他需要在董事会层面做出改变。其中之一应是改进负责这些交易的团队,因为显然他们的表现充其量只能说是平庸。”周二,诺华以120亿美元收购美国公司Avidity获得的一款肌肉萎缩症药物在后期研究中失败,导致公司股价暴跌逾10%,市值蒸发近300亿美元。此前一天,心脏药物pelacarsen的结果令投资者失望。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10